Jordan Simpson, MD
Adult Reconstructive Orthopaedic Surgery · Lubbock, TXNPI 1104143957
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Stryker accounts for 82.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $3,706 and has fallen 92.5% since, to $279 in 2025. That places this record below the midpoint for adult reconstructive orthopaedic surgery clinicians in TX, where the typical reported total is $14,244.
Across 98 payments — averaging $94.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$8K
- Medical Device Business Services, Inc.$602
- Bioventus LLC$316
- Johnson & Johnson$295
- Zimmer Biomet$131
- Exactech, Inc.$91
- plus $227 from 11 others
What the payments were for
- Consulting fees$4505%
- Travel & lodging$3,71740%
- Food & beverage$5,11455%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 64 | $7,619 |
| Medical Device Business Services, Inc. | 4 | $602 |
| Bioventus LLC | 11 | $316 |
| Johnson & Johnson | 6 | $295 |
| Zimmer Biomet | 1 | $131 |
| Exactech, Inc. | 1 | $91 |
| Baxter Healthcare | 1 | $32 |
| Abbott | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Innovation Technologies Inc | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Smith+Nephew | 1 | $19 |
| Orthofix Medical, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$4,492
- BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION$1,736
- TRIATHLON$139
- Verasense$139
- AEQUALIS PERFORM REVERSED$131
- AEQUALIS PERFORM$131
- Persona$131
- ATTUNE$130
- ACCOLADE$118
How this compares
$9,281 in reported general payments places this provider in the 35th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.
See all adult reconstructive orthopaedic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZilrettaTriamcinolone Acetonide | 25 | $25,153 |
| XareltoRivaroxaban | 45 | $10,202 |
| Celecoxib | 206 | $7,921 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 410 | $4,698 |
| Methocarbamol | 342 | $2,528 |
| Tranexamic Acid | 92 | $1,137 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 100 | $973 |
| Gabapentin | 111 | $825 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 107 | $643 |
| Dexamethasone | 95 | $577 |
| Cephalexin | 31 | $568 |
| Tramadol Hcl | 134 | $509 |
| Ondansetron OdtOndansetron | 20 | $368 |
| Tizanidine Hcl | 23 | $362 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 29 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pacira Pharmaceuticals IncorporatedZilretta | $21 | $25,15325 claims |
| Johnson & JohnsonXarelto | $295 | $10,20245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.
Other adult reconstructive orthopaedic surgery in Lubbock
- Tyler GoldbergAustin$4.6M
- Antonia ChenDallas$3.8M
- John BarringtonPlano$2.2M
- Roger EmersonPlano$691K
- Donald HohmanDallas$537K
- Steven WeedenFort Worth$370K
- Marcus FordFort Worth$296K
- Raul MarquezEdinburg$278K
- Richard ReitmanPlano$227K
- Brian FullerCarrollton$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.